PROMISE: CE/BZA in postmenopausal, ER+ ductal carcinoma in situ - VJOncology Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the Phase II PROMISE study (NCT02694809), which assesses...

⭐ Swati Kulkarni, MD, discusses the PROMISE study, assessing presurgical use of conjugated CE/BZA in postmenopausal women with ER-positive DCIS:

🎥 buff.ly/FJvSAAR

@ascocancer.bsky.social #ASCO25 #BreastCancer #CTSM #TrialUpadte #SurgOnc